Page 17 - <>期刊 v2

17
Back ID D N U | iddnu@suntrap.com | www.suntrap.com

takes effects quickly to inhibit the replication of the virus, eliminates inflammation of the respiratory tract and lungs,
slows down breathing difficulties, and quickly excretes sputum to relieve symptoms; (3) it can reduce lung inflammation
and oxidative stress, prevent cell damage that leads to the formation of myofibroblasts, and postpone tissue fibrosis;
(4) it can regulate the expression of pro-apoptotic factors and apoptosis-inhibiting factors, repair damaged lung tissue,
and reverse tissue fibrosis.

Currently, in-depth verifications of the sequelae of the SARS-CoV-2 infection (e.g., loss of taste, central nervous system,
and peripheral nervous system damage) are still in progress.

The pandemic of COVID-19 has been lasting for nearly two years. Its mutant strains are constantly emerging, and the
global incidence rate continues to rise. To date, Suntrap research team has made a certain degree of a breakthrough in
the design of multi-target anti-coronavirus drugs. It is necessary to accelerate the clinical verification and strengthen
cooperation. To conduct more in-depth clinical research for LeSoleil anti-SARS-CoV-2 drugs, and make COVID-19 not to
be an obstacle for social stability, economic development and human health, Suntrap recruits qualified clinical research
institutions around the world to carry out clinical revalidation studies on the efficacy of the LeSoleil broad-spectrum
anti-coronavirus series of drugs against their known mutant strains from SARS-CoV-2.

Consult www.suntrap.com or search for “IDDNU” and “suntrap” to find related reports.

Suntrap Life Technologies Ltd.
Suntrap Health & Environment Research Institute